Algorae Pharmaceuticals (ASX:1AI) has moved to strengthen its financial footing, announcing a $3.9 million capital raise to scale its commercial operations and advance its artificial intelligence-driven research pipeline.
The company confirmed it had “successfully raised $3,988,183 (before costs),” drawing funds from a combination of option exercises and a placement to what it described as “sophisticated, long-term shareholders.”
The placement was completed at $0.012 per share, representing a discount to recent trading levels.
With the raise complete, Algorae said its balance sheet has been materially strengthened. The company now holds a pro forma cash balance of approximately $5.56 million, alongside access to a $3 million receivables-based debt facility. This improved liquidity is expected to support expansion across its two core divisions.
The company stated that “net proceeds will significantly strengthen the Company's working capital position as it scales its commercial portfolio under AlgoraeRx and advances its R&D pipeline under AlgoraeOS,” highlighting its dual-track model.
AlgoraeRx focuses on sourcing and supplying generic and specialty medicines across Australia and New Zealand, while AlgoraeOS represents the company’s proprietary AI platform designed to identify synergistic drug combinations and guide preclinical development.
Management signalled confidence that the additional capital will allow the company to build on recent progress, noting that the “strengthened balance sheet positions Algorae to capitalise on the commercial and scientific momentum generated over recent months.”
The broader ambition remains to bridge artificial intelligence with pharmaceutical development, using computational methods to accelerate discovery while maintaining a parallel revenue stream through commercialisation. By combining these approaches, Algorae aims to translate AI-driven insights into viable therapies while expanding access to existing medicines.